Trial Profile

A pivotal trial of Legutaxel in multiple cancers including lung cancer, gastric cancer, and ovarian cancer

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 22 Dec 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs QHL 236 (Primary)
Indications Gastric cancer; Lung cancer; Ovarian cancer; Solid tumours
Focus Registrational; Therapeutic Use
Sponsors Shanghai Affinity Biopharmaceutical

Most Recent Events

22 Dec 2023 New trial record
07 Jul 2023 According to Affinity Biopharma media release, company plans to carry out pivotal trial in multiple cancers including lung cancer, gastric cancer, and ovarian cancer.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com